Want to see CRBP full AI Analyst Report?
CRBP Stock Chart & Stats
$10.59
-$0.10(-0.79%)
At close: 4:00 PM EST
$10.59
-$0.10(-0.79%)
Day’s Range― - ―
52-Week Range$7.12 - $20.56
Previous CloseN/A
Volume39.58K
Average Volume (3M)503.64K
Market Cap
$178.98M
Enterprise Value$76.07M
Total Cash (Recent Filing)$138.60M
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 11, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding18,527,796
10 Day Avg. Volume744,820
30 Day Avg. Volume503,638
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-510.54
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$38.50Price Target Upside263.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.64
Revenue Forecast (FY)$1.67M
Bulls Say, Bears Say
Bulls Say
Strong Cash Runway And Low LeverageA cash balance around $138M combined with minimal debt and sizable equity provides multi-year funding flexibility to execute registrational trials. This reduces near-term solvency risk, allowing the company to advance CRB-701 and CRB-913 without immediate commercial revenue pressure.
Promising CRB-701 Efficacy And FDA AlignmentHigh objective response rates with durable responses and a manageable safety profile, plus FDA agreement on a registrational path, materially de-risks late-stage development. If replicated in phase 3, this could establish CRB-701 as a meaningful targeted option in underserved HPV-driven tumors.
Executive And Governance Build-outHiring experienced clinical, BD and commercialization leaders and adding an independent oncology director strengthens execution capability for registrational programs and future partnerships. Improved governance and equity reserves support talent retention and deal-making capacity through late-stage development.
Bears Say
Pre-revenue With Widening Net LossesOperating without product revenue and with rapidly widening losses creates structural dependency on external financing and milestone events. Continued negative earnings erode equity over time and amplify execution risk if clinical readouts or fundraising stall, pressuring long-term stability.
Accelerating Cash Burn And Negative Free Cash FlowSteadily rising operating cash outflows and negative free cash flow materially increase the likelihood of dilution or program slowdowns absent new financing. Even with current cash, persistent high burn limits optionality and heightens risk around multi-site registrational builds and commercialization investments.
Reliance On Collaborations And Financing For RevenueWithout commercial products, the firm's model depends on partnership milestones and capital markets access. This creates dependency on successful trial outcomes and favorable deal terms, exposing shareholders to dilution and execution risk if trials underperform or partnering markets tighten.
Corbus Pharmaceuticals News
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $7.12 and its highest was $20.56 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $178.98M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.221 by -$0.009.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.26.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 18,527,796 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.221. Following the earnings report the stock price went up 3.533%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.50 (263.55% Upside)
$38.50 (263.55% Upside)
Hedge Fund Trend
Decreased
By 15.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $101.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.19%
12-Months-Change
Fundamentals
Return on Equity
-70.89%
Trailing 12-Months
Asset Growth
3.25%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
CRBP Stock 12 Month Forecast
Average Price Target
$38.50
▲(263.55% Upside)
Technical Analysis
Ownership Overview
15.58% Insiders
5.30% Mutual Funds
<0.01% Other Institutional Investors
70.25% Public Companies and
Individual Investors